After the market closed on the 18th, 昭栄薬品 sharply revised upward its consolidated earnings outlook for the interim period through September. Net sales are now expected to increase from ¥13.54 billion to ¥15.836 billion, operating income from ¥208 million to ¥424 million, and net income from ¥204 million to ¥351 million. The company attributed the revision to order volumes from domestic customers exceeding expectations and progress in passing on higher costs amid elevated natural fats and oils prices.
After the market closed on the 18th, 昭栄薬品 revised its earnings outlook for the interim period through September upward. It raised its forecasts for net sales from the previous ¥13.54 billion to ¥15.836 billion, operating income from ¥208 million to ¥424 million, and net income from ¥204 million to ¥351 million. All three figures represent substantial increases from the year-earlier period.
The revision reflects moves by customers in the chemicals business to build inventories in preparation for supply risks, among other factors. Higher-than-expected order volumes from major domestic customers boosted net sales and earnings.
The company also said that progress in passing on higher sales prices amid persistently elevated natural fats and oils prices contributed to an improvement in gross profit.
The revision is based on formal disclosure information, and the company’s future earnings trends will continue to be closely watched.